title: Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
abstract: Sarcomas represent a rare and heterogeneous disease, and the prognosis of patients with unresectable or advanced metastatic bone and especially soft-tissue sarcomas remains poor, with a disease-free survival of less than 10% at 5 years. Only few chemotherapeutic agents have been identified to be active, with reported response rates for doxorubicin, epirubicin and ifosfamide above 20%. Although combination therapy with different chemotherapeutic substances results in higher response rates, superiority against single-agent chemotherapy in terms of survival has not been demonstrated yet. Regarding anthracyclines, and ifosfamide in particular, a dose-response relationship has been shown, and high-dose chemotherapy with stem cell support has also been evaluated by several investigators. However, all studies comprised small patient cohorts and included very heterogeneous histological subtypes of soft-tissue sarcoma. Moreover, randomized trials are missing. Nevertheless, higher doses of chemotherapy result in higher response rates possibly correlating with longer survival. Finally, well-designed randomized trials should be performed, preferably in younger patients and in the context of an interdisciplinary treatment approach. In this review, we provide an overview of the literature concerning high-dose chemotherapy with hematopoietic stem cell support in the treatment of bone and soft-tissue sarcomas. On the basis of our own data, we would like to emphasize the importance of high-dose chemotherapy in the treatment of sarcomas.
authors.affiliation: University of Heidelberg, Department of Internal Medicine V, Heidelberg, Germany. Bernd_Kasper@med.uni-heidelberg.de
authors.forename: Bernd
authors.initials: B
authors.lastname: Kasper
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Ho
authors.forename: Gerlinde
authors.initials: G
authors.lastname: Egerer
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D019046:Bone Marrow Neoplasms / Q000188:drug therapy; D001859:Bone Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000188:drug therapy*; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy; D016019:Survival Analysis; D016896:Treatment Outcome